664364-60-7 Usage
General Description
N-Cbz-3-Methylnipecotic acid ethyl ester is a chemical compound used primarily in scientific research. The term “N-Cbz” refers to the carboxybenzyl protection group attached to the compound, which is commonly used in peptide synthesis. The "3-Methylnipecotic acid" part indicates the presence of a nipecotic acid derivative, which is of interest due to nipecotic acid's role as an inhibitor of gamma-aminobutyric acid (GABA) uptake. The addition of "ethyl ester" implies an ester functional group, which enhances the compound's solubility and allows for more efficient chemical reactions. N-Cbz-3-Methylnipecotic acid ethyl ester is typically prepared in a laboratory setting and is not naturally occurring.
Check Digit Verification of cas no
The CAS Registry Mumber 664364-60-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,4,3,6 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 664364-60:
(8*6)+(7*6)+(6*4)+(5*3)+(4*6)+(3*4)+(2*6)+(1*0)=177
177 % 10 = 7
So 664364-60-7 is a valid CAS Registry Number.
InChI:InChI=1/C17H23NO4/c1-3-21-15(19)17(2)10-7-11-18(13-17)16(20)22-12-14-8-5-4-6-9-14/h4-6,8-9H,3,7,10-13H2,1-2H3
664364-60-7Relevant articles and documents
DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF
-
, (2013/03/26)
The present invention provides compounds of Formula (I) or a stereo isomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 rece
Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
-
Page/Page column 41, (2008/06/13)
The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.